Spikimm is a biotech company co-created by Truffle Capital and Institut Pasteur with the objective of developing an effective treatment against SARS-CoV2 and its major variants.
Spikimm has obtained an exclusive worldwide license for ultra-potent, broad-spectrum monoclonal antibodies directed against the Spike protein of SARS-CoV2.
These "ultra-potent" monoclonal antibodies have shown strong efficacy in in vivo (rodent) trials. They are potentially effective on all concerned variants.
These "new generation" antibodies will ideally be administered as monotherapy, and by a route of administration compatible with conventional medicine (subcutaneous or intramuscular).